Key Takeaways SRPT dropped nearly 10% as Dyne Therapeutics advanced a rival exon 51 skipping DMD therapy toward approval.Sarepta faces added pressure after Elevidys' label restrictions and growing competition in DMD treatments.SRPT trades below the industry P/B average, while 2026 and 2027 EPS estimates have declined. Shares of Sarepta Therapeutics (SRPT - Free Report) fell nearly 10% over the past week. This decline likely reflects growing investor concerns about the company’s position in the Duchenne muscular dystrophy (DMD) landscape following a key regulatory milestone for rival Dyne Therapeutics (DYN - Free Report) .
On Monday, DYN announced that the FDA accepted its regulatory filing seeking approval for the DMD therapy zeleciment rostudirsen (z-rostudirsen, or DYNE-251). The application was granted priority review, with the agency expected to make a final decision by Jan. 21, 2027. If approved, the Dyne Therapeutics drug could emerge as a competitive threat to Sarepta’s Exondys 51, as both therapies target DMD patients amenable to exon 51 skipping.
Exondys 51, approved in 2016, was the first FDA-approved treatment for DMD patients amenable to exon 51 skipping and remains the standard of care for this patient population. However, z-rostudirsen could challenge its market position if approved. Unlike Sarepta’s drug, which requires once-weekly infusions, Dyne’s drug is administered once every four weeks, potentially offering greater convenience for patients and caregivers. Analysts also point to cross-study comparisons suggesting that z-rostudirsen achieved higher dystrophin expression than Exondys 51, further strengthening its competitive profile.
The latest development comes as Sarepta shares were beginning to stabilize following a steep selloff triggered by safety concerns surrounding the company's DMD gene therapy, Elevidys. Investor sentiment deteriorated after two patient deaths following treatment with Elevidys prompted the FDA to significantly restrict the therapy's label to ambulatory DMD patients and add a boxed warning for acute liver injury. With Elevidys representing a key growth driver for Sarepta, the regulatory setback had already raised concerns about the company's growth outlook. Against this backdrop, Dyne's regulatory progress has added to investor concerns about Sarepta's competitive position in DMD.
Growing Competition in the DMD SpaceApart from Dyne Therapeutics, Sarepta faces competition from several other emerging players. These include Regenxbio (RGNX - Free Report) , Wave Life Sciences (WVE - Free Report) and Solid Biosciences, which are developing next-generation RNA or gene therapy approaches for the treatment of DMD.
SRPT’s Price Performance, Valuation & EstimatesShares of Sarepta have underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Sarepta is at a discount to the industry. Based on the price/book (P/B) ratio, the company’s shares currently trade at 1.14 times trailing book value, lower than the industry’s average of 3.44.
Image Source: Zacks Investment Research
Over the past 30 days, the Zacks Consensus Estimate for 2026 EPS has declined from $4.84 to $4.77, while that for 2027 has fallen from $3.02 to $2.90.
Image Source: Zacks Investment Research
Sarepta currently has a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, Aug. 5, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentati.
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) against certain of its officers and directors for alleged breaches of fiduciary duty.
Shareholders who have held Sarepta shares continuously since prior to June 22, 2023, may have standing to seek corporate governance reforms, the return of funds back to the company, and a court-approved incentive award, all at no cost to them.
What Should Sarepta Shareholders Do?
If you have held Sarepta shares continuously since prior to June 22, 2023, you may have standing to seek corporate governance reforms at Sarepta, including improvements to internal controls, transparency, and executive oversight.
To learn more, visit: https://www.johnsonfistel.com/investigations/sarepta-therapeutics/ or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471.
There is no cost or obligation to you.
What Is Johnson Fistel Investigating?
A previously filed class action complaint alleges that Sarepta and certain of its executives made materially false and misleading statements, and/or failed to disclose material adverse facts, concerning the safety profile and regulatory and commercial prospects of ELEVIDYS, the Company's gene therapy for Duchenne muscular dystrophy.
According to the complaint, Sarepta allegedly failed to disclose that ELEVIDYS posed significant safety risks to patients and that the Company's trial regimes and protocols failed to detect severe side effects.
The complaint further alleges that serious adverse events associated with ELEVIDYS would cause Sarepta to halt recruitment and dosing in certain trials, attract regulatory scrutiny, and create greater risks concerning the therapy's existing and expanded approvals. When Sarepta disclosed patient deaths associated with acute liver failure following treatment and subsequent safety and regulatory developments, investors allegedly suffered losses.
About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investor Rights:
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on U.S. exchanges. For more information about the firm and how we may be able to help you recover your losses, please visit www.johnsonfistel.com.
Achievements:
In 2024, Johnson Fistel was ranked in the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. The firm has recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel, marking the eighth time it has been recognized among the top U.S. plaintiffs' securities law firms.
Attorney Advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Contact:
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq.
(619) 814-4471 [email protected] or [email protected]
Buying shares of excellent companies that have fallen out of favor is a great way to earn superior returns over the long run. However, investors should be careful not to catch a falling knife. Corporations often fail to keep up with broader equities for good reasons, and in many cases, it's not worth investing in market laggards, even on the dip. With that as a backdrop, let's consider two stocks that have moved in the wrong direction this year but remain unattractive at their current levels: Recursion Pharmaceuticals (RXRX 5.32%) and Sarepta Therapeutics (SRPT 7.65%).
Image source: Getty Images.
1. Recursion Pharmaceuticals Recursion Pharmaceuticals is a drugmaker that relies on artificial intelligence (AI) to go from discovery to the market. The company is betting that its approach can succeed where other breakthroughs have failed: Even with significant technological progress over the past few decades, the cost and time required to develop drugs have increased. Recursion Pharmaceuticals uses an AI-powered algorithm to predict which candidates are the most likely to perform well in clinical trials and, eventually, earn approval.
To its credit, the company has several promising products in its pipeline. For instance, Recursion Pharmaceuticals' REC-4881 is an investigational medicine for familial adenomatous polyposis (FAP), a rare disorder that leads to the development of precancerous polyps in the colon and rectum, giving patients a very high risk of colorectal cancer if left untreated. REC-4881 has demonstrated encouraging reductions in precancerous polyp burden in early clinical studies.
Given that the U.S. Food and Drug Administration has never approved any medicine for FAP, REC-4881 could present an attractive commercial opportunity if it proves effective in late-stage clinical trials.
Today's Change
(
-5.32
%) $
-0.20
Current Price
$
3.56
That said, there are several problems with Recursion Pharmaceuticals, one of which is that it has no products on the market, and none even in late-stage studies. For a company that claims to be bringing about a paradigm shift in the industry, we'd expect greater success. Perhaps it just hasn't had time yet, but Recursion Pharmaceuticals was founded in 2013. Second, although Recursion Pharmaceuticals may have hoped to build a competitive advantage through its focus on AI -- and eventually license its AI-powered operating system for drug discovery -- other corporations are making strides in this field.
Third, like every biotech company, it runs the risk of clinical or regulatory setbacks that could sink its share price. Those are some of the reasons Recursion Pharmaceuticals' stock has moved in the wrong direction and may continue doing so. It's not an attractive company for most investors, though contrarians with a strong tolerance for volatility may consider initiating a small position.
2. Sarepta Therapeutics Last year, Sarepta Therapeutics faced significant challenges. Two patients taking the company's Elevidys, a medicine for a rare, progressive, neuromuscular disease called Duchenne muscular dystrophy (DMD), unfortunately died after developing acute liver failure (ALF). Sarepta Therapeutics was able to keep Elevidys on the market, but only for ambulatory DMD patients -- it is no longer indicated for non-ambulatory patients. Further, it now includes a boxed warning for acute liver injury (ALI) and ALF.
In fairness, Sarepta Therapeutics has made progress in overcoming these obstacles. The company is testing whether administering sirolimus (an immunosuppressant) before and after Elevidys infusion can help reduce the risk of ALF and ALI in non-ambulatory patients.
Today's Change
(
-7.65
%) $
-1.57
Current Price
$
18.95
Elsewhere, the company has requested full approval for two of its other DMD medicines, Amondys 45 and Vyondys 53. Both were previously under accelerated approval, meaning they had to undergo confirmatory studies to confirm efficacy. Sarepta Therapeutics is also developing newer medicines for a range of other diseases. Solid clinical progress might jolt the stock.
However, there remain significant risks. Even with clinical progress with newer candidates and full approval for Amondys 45 and Vyondys 53, Elevidys remains central to Sarepta's prospects because it addresses the underlying genetic causes of DMD. If the company fails to show that giving patients sirolimus can mitigate Elevidys' adverse events, the stock will fall off a cliff. Even if it can prove that non-ambulatory patients have a lower risk of ALI and ALF when they also receive sirolimus, it will be hard for Sarepta Therapeutics to protect its market share as new DMD medicines gain approval.
That's why it's difficult for long-term investors to justify investing in the company, especially given the many attractive biotech stocks on the market.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 30 individuals hired by Sarepta in the second quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received in the aggregate 151,305 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta’s common stock.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com or follow us on LinkedIn, X, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
• Sarepta Therapeutics shares are climbing with conviction. What’s fueling SRPT momentum?
The FDA approved VYONDYS 53 in 2019 and AMONDYS 45 in 2021.
The agency set a Prescription Drug User Fee Act target action date of Feb. 28, 2027.
The applications are supported by findings from the Phase 3 ESSENCE confirmatory study, along with published real-world evidence and the established safety profiles of both exon-skipping therapies.
Louise Rodino-Klapac, president of research and development and technical operations at Sarepta, said that more than 1,800 patients worldwide have received Sarepta’s exon-skipping therapies, with continued observations suggesting preservation of muscle function and slower disease progression.
ESSENCE Data and Real-World Evidence Support ApplicationsSarepta said the ESSENCE study did not meet its primary endpoint, although treatment groups showed numerical advantages over placebo.
The company said additional post-hoc analyses addressing disease progression variability and the effects of the COVID-19 pandemic found increased dystrophin expression at week 96, and consistent reductions in four-step ascend decline across multiple analyses.
The therapies were also well tolerated through 144 weeks, with no new safety signals reported.
According to Sarepta, published real-world studies have linked VYONDYS 53 to a 7.5-year delay in the need for nighttime ventilation, while AMONDYS 45 has been associated with slower declines in lung function and delayed need for cough assist devices.
Across its phosphorodiamidate morpholino oligomer portfolio, the company also cited evidence suggesting benefits in survival, delayed loss of ambulation, improved cardiac outcomes, and fewer hospital visits.
SRPT Stock Price Activity: Sarepta Therapeutics shares were up 5.93% at $18.03 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administratio
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Applications (sNDAs) for AMONDYS 45® (casimersen) and VYONDYS 53® (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action data of February 28, 2027. The sNDA.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Sarepta Therapeutics (SRPT) and Prothena (PRTA). But which of these two stocks is more attractive to value investors?
It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT - Free Report) . Shares have added about 24.2% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Sarepta Therapeutics due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Sarepta Therapeutics, Inc. before we dive into how investors and analysts have reacted as of late.
Wider-Than-Expected in Q4, Sales Beat EstimatesSarepta reported a fourth-quarter 2025 adjusted loss of $3.58 per share, wider than the Zacks Consensus Estimate of a loss of 71 cents. This higher-than-anticipated loss was attributed to an increase in operating expenses incurred during the quarter. In the year-ago period, the company posted an adjusted EPS of $1.91.
The adjusted figures exclude depreciation and amortization costs, stock-based compensation expenses, gains on strategic investments, losses on debt extinguishment and restructuring charges. Including these items, the loss during the quarter was $3.93 against an EPS of $1.50 in the year-ago period.
Sarepta recorded total revenues of $442.9 million, down nearly 33% year over year. This downtick was due to lower sales of Elevidys. The reported figure beat the Zacks Consensus Estimate of $408.5 million.
Quarter in DetailProduct revenues fell 42% year over year to $369.6 million.
The company recorded $259 million from the product sales of its three PMO therapies, up 2% year over year. The figure missed the Zacks Consensus Estimate of $270 million.
Sarepta generated $110 million from Elevidys sales, down more than 71% year over year, primarily due to its decision to suspend shipments to non-ambulatory patients in June 2025 amid safety concerns. The therapy’s sales missed the Zacks Consensus Estimate of $114 million.
SRPT recorded approximately $73.3 million in collaboration and other revenues, compared to $20.3 million in the year-ago period. This uptick was mainly due to higher contract manufacturing revenues, driven by higher volume of shipments of Elevidys to Roche.
Adjusted research and development (R&D) expenses totaled $308.1 million, up 78% year over year. This upside is primarily due to an increase in milestone expenses made toward pipeline development during the quarter.
Adjusted selling, general & administrative (SG&A) expenses declined 20% to $105.4 million, primarily due to the company’s restructuring plan launched in July 2025.
Full-Year 2025 ResultsSarepta reported total revenues of $2.2 billion, up 16% year over year.
The adjusted loss in 2025 stood at $5.05 per share against adjusted EPS of $3.71 in the year-ago period.
2026 GuidanceAt the conference call, management issued fresh guidance for net product revenue projection for full-year 2026. It expects figures between $1.2 billion and $1.4 billion. The company projects total collaboration, contract manufacturing and royalty revenues to be between $450 million and $550 million.
Sarepta reiterated its guidance for expenses. It expects the combined adjusted R&D and SG&A expenses to be in the $800-$900 million range.
How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in estimates revision.
The consensus estimate has shifted 9.79% due to these changes.
VGM ScoresAt this time, Sarepta Therapeutics has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a score of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions looks promising. Interestingly, Sarepta Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry PlayerSarepta Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Prothena (PRTA - Free Report) , a stock from the same industry, has gained 10.2%. The company reported its results for the quarter ended December 2025 more than a month ago.
Prothena reported revenues of $0.02 million in the last reported quarter, representing a year-over-year change of -99.1%. EPS of -$0.44 for the same period compares with -$1.08 a year ago.
Prothena is expected to post a loss of $0.37 per share for the current quarter, representing a year-over-year change of +67%. Over the last 30 days, the Zacks Consensus Estimate has changed +4.1%.
Prothena has a Zacks Rank #2 (Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size. That equal-weight structure separates it from cap-weighted peers and creates both opportunity and risk that investors need to understand clearly right now.
The fund carries over $8 billion in assets across 150+ holdings, with 96% of the portfolio in healthcare. XBI is up about 2% year to date, but that calm surface masks a rougher month: shares pulled back roughly 4% over the past 30 days. The one-year picture is far more compelling, with the fund up 46% over the past year. Zoom out five years, though, and the fund is still down about 6%, a reminder of how brutal the 2021-2022 rate-driven selloff was for biotech.
The FDA’s New Leadership Changes the Calculus for Every Holding The single biggest macro factor shaping XBI’s next 12 months is the FDA regulatory environment under its new leadership. Marty Makary was confirmed as FDA Administrator, resolving genuine uncertainty about who would run the agency. That clarity matters because biotech valuations are built almost entirely on the probability of regulatory approval, and an unpredictable FDA is a discount rate in itself.
The concern now is not who sits at the top but what is happening beneath. DOGE-related staffing reductions and broader HHS restructuring have raised questions about review capacity and advisory committee continuity. A slower approval pipeline would compress valuations across XBI’s 150+ holdings simultaneously, hitting small and mid-cap names hardest because they have no commercial revenue to cushion the blow.
Watch the FDA’s published PDUFA action dates and advisory committee calendars monthly. A pattern of delays or unexpected refusals would be the clearest warning sign. A steady approval cadence through mid-2026 would confirm that operational disruption has been contained.
Equal Weight Means Every Clinical Readout Hits the Whole Fund Because each holding starts at roughly the same portfolio weight, a single binary clinical event, whether a phase 3 success or failure, moves the fund in a way that a cap-weighted index would barely register.
Several holdings have high-stakes readouts coming. Moderna (NASDAQ:MRNA | MRNA Price Prediction), currently the fund’s largest position at about 2.3% weight, expects phase 3 norovirus and adjuvant melanoma data in 2026. Moderna is up about 82% year to date, driven partly by a patent settlement that sparked a sharp sentiment reversal on Reddit. A post on r/wallstreetbets titled “Moderna +10% after-hours as Moderna agrees to pay up to $2.25B to settle COVID vaccine patent dispute” captured the mood shift, accumulating 270 upvotes by March 5.
Krystal Biotech (NASDAQ:KRYS) is the fund’s quiet fundamental standout, posting 94% gross margins and $204 million in net income for full-year 2025, with VYJUVEK revenue growing 34% year over year. Phase 3 readouts in corneal DEB and neurotrophic keratitis are both expected before year-end.
Sarepta Therapeutics (NASDAQ:SRPT) is attempting a recovery after ELEVIDYS revenue fell 33% year over year in Q4 2025 following a safety-driven suspension of non-ambulatory shipments. Management expects to return to profitability in 2026, but the path depends on label rehabilitation and a Japan launch that began in February.
The quarterly rebalance is where this mechanic becomes most visible. XBI rebalances in March, June, September, and December, equalizing weights each time: strong performers get trimmed and beaten-down names get topped up. Watch the holdings file after each rebalance to see which names gained or lost weight, particularly whether high-burn, pre-revenue names like Recursion Pharmaceuticals (NASDAQ:RXRX), down 23% year to date amid dilution concerns from a $300 million ATM equity offering, are being added to or reduced from the portfolio.
If the FDA maintains consistent review timelines through mid-2026 and the June rebalance does not materially increase exposure to high-burn names with no near-term catalysts, XBI’s one-year momentum has a credible foundation. If either condition breaks, the equal-weight structure that amplified the upside will amplify the downside just as efficiently.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in the first quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received in the aggregate 113,855 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta’s common stock.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com or follow us on LinkedIn, X, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each offering a differentiated mechanism, commercial traction, or platform technology that a deep-pocketed acquirer would find difficult to replicate organically.
Incyte Incyte (NASDAQ: INCY | INCY Price Prediction) tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.
The stock trades at roughly 14x trailing earnings with an analyst consensus target of $107.14, suggesting meaningful acquisition premium headroom. CEO Bill Meury noted the company enters 2026 with “strong business momentum, an innovative, strategically focused pipeline, and a clear strategy for capital allocation and long-term growth.” The primary risk remains Jakafi patent exposure, but the breadth of the franchise mitigates single-asset concentration.
Alnylam Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ: ALNY) represents the most transformative platform play on this list. FY2025 revenue surged 65.2% YoY to $3.71 billion, with AMVUTTRA generating $826.6 million in Q4 2025 (+189% YoY) following its landmark ATTR-CM approval. The company achieved full-year GAAP profitability for the first time in 2025 with net income of $313.7 million. 2026 guidance calls for $4.9 billion to $5.3 billion in total net product revenues.
At a $43.9 billion market cap and trading down 16.8% YTD, Alnylam’s RNAi platform spanning cardiovascular, neurological, and rare disease indications would deliver unmatched therapeutic breadth to a strategic acquirer. The analyst consensus target is $449.32, implying substantial upside from current levels near $333 a share.
Kymera Therapeutics This company’s targeted protein degradation platform has attracted collaborations from both Sanofi and Gilead Sciences, validating its first-in-class approach. Kymera Therapeutics (NASDAQ: KYMR) stock has surged 204.3% over the past year, reflecting growing conviction in its STAT6 degrader program. Phase 1b data for KT-621 in atopic dermatitis showed results in line with or numerically exceeding dupilumab after four weeks.
The company holds approximately $1.62 billion in cash with runway into 2029 and recently initiated dosing in its KT-579 Phase 1 trial in February 2026, the first IRF5-directed mechanism in the clinic. The CDK2 molecular glue program with Gilead carries up to $750 million in total potential payments and is directly relevant to oncology acquirers. Analysts maintain a consensus target of $119.14, versus a current price near $83 per share.
Arcus Biosciences Arcus Biosciences (NASDAQ: RCUS) holds what management describes as a best-in-class HIF-2α inhibitor in casdatifan, with Phase 1 data showing a 45.2% confirmed ORR and 15.1-month median PFS at the Phase 3 dose in IO-experienced clear cell RCC. CEO Terry Rosen cited “an over $5 billion peak sales opportunity” across IO-experienced and first-line ccRCC settings.
With a $2.7 billion market cap and $1.01 billion in cash providing runway to at least H2 2028, Arcus offers an acquirer a clean balance sheet and multiple Phase 3 readouts ahead. The stock trades well below analyst consensus of $33.80 and is down 9.4% YTD, potentially creating an attractive entry point before PEAK-1 data materializes.
Sarepta Therapeutics The M&A appeal here is rooted in deep valuation compression. Sarepta Therapeutics (NASDAQ: SRPT) stock has fallen 65.9% over the past year, pushing its market cap to roughly $2.3 billion against FY2025 revenue of $2.20 billion. ELEVIDYS remains the only approved gene therapy for ambulatory DMD patients, and its Japan launch by Chugai in February 2026 is expected to trigger a $40 million milestone payment. The siRNA pipeline includes five clinical-stage RNAi programs targeting rare neurological diseases.
CEO Doug Ingram stated the company entered 2026 with “solid financial footing…durable approved therapies…exciting, potentially best-in-class siRNA pipeline.” Regulatory overhang on ELEVIDYS and a deep EPS miss of −$3.58 versus the −$1.05 consensus in Q4 2025 weigh on sentiment, but the price-to-sales ratio of 0.978x reflects a historically rare discount for a commercial-stage gene therapy franchise.
Conclusion Across these five names, several themes emerge: validated novel platforms (RNAi, TPD, gene therapy), oncology pipeline depth, and depressed valuations relative to clinical and commercial potential. The most immediate M&A candidates are Arcus and Sarepta, given their compressed market caps, while Incyte and Alnylam offer scale and revenue durability that would appeal to a larger strategic buyer. Kymera’s platform optionality across oncology and immunology makes it a longer-duration but high-conviction target. Key uncertainties include Phase 3 replication risk for casdatifan, regulatory resolution for ELEVIDYS, and the timing of KT-621 Phase 2b data, all of which could materially shift acquisition premiums in either direction.
Aberdeen Group plc increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 13.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,251,593 shares of the biotechnology company's stock after purchasing an additional 268,829 shares during the
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentation.
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2026. "We entered 2026 with clear priorities—stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta's next era. In the first quarter, we made meaningful progress against each,” said Doug Ingram, chief executive officer, Sarept.
Sarepta Therapeutics (SRPT - Free Report) came out with quarterly earnings of $3.16 per share, beating the Zacks Consensus Estimate of $0.9 per share. This compares to a loss of $3.42 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +253.07%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.71 per share when it actually produced a loss of $3.58, delivering a surprise of -404.23%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Sarepta Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $730.8 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 56.20%. This compares to year-ago revenues of $744.86 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Sarepta Therapeutics shares have added about 1.3% since the beginning of the year versus the S&P 500's gain of 6%.
What's Next for Sarepta Therapeutics?While Sarepta Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Sarepta Therapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.06 on $446.54 million in revenues for the coming quarter and $3.90 on $1.74 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Foghorn Therapeutics Inc. (FHTX - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026.
This company is expected to post quarterly loss of $0.28 per share in its upcoming report, which represents a year-over-year change of +6.7%. The consensus EPS estimate for the quarter has been revised 3.5% lower over the last 30 days to the current level.
Foghorn Therapeutics Inc.'s revenues are expected to be $9.24 million, up 55.2% from the year-ago quarter.
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Key Takeaways Sarepta posted Q1 EPS of $3.16 and revenues of $730.8M, topping consensus estimates.SRPT's Elevidys sales fell 73% after the suspension to non-ambulatory patients.Sarepta maintained 2026 product revenue guidance of $1.2B-$1.4B amid pipeline progress. Sarepta Therapeutics, Inc. (SRPT - Free Report) reported a first-quarter 2026 adjusted earnings per share (EPS) of $3.16, which beat the Zacks Consensus Estimate of 90 cents. In the year-ago quarter, the company posted a loss of $3.42 per share due to a one-time charge incurred to close the multi-billion-dollar collaboration deal with Arrowhead Pharmaceuticals .
The adjusted figures exclude depreciation and amortization costs, stock-based compensation expenses, gains on strategic investments and certain interest expense/income. Including these items, EPS during the quarter was $2.88 against a loss of $4.60 in the year-ago period.
Sarepta recorded total revenues of $730.8 million, down 2% year over year. This downtick was due to lower sales of Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD). Yet, the figure beat the Zacks Consensus Estimate of about $468 million.
SRPT’s Stock PerformanceYear to date, Sarepta’s shares have gained 7% against the industry’s 2% decline.
Image Source: Zacks Investment Research
More on SRPT’s EarningsSarepta’s commercial portfolio includes three approved RNA-based PMO therapies — Exondys 51, Vyondys 53 and Amondys 45 — and Elevidys, all targeting DMD. Product revenues fell 46% year over year to $330.5 million.
The company recorded $228.6 million from the product sales of its three PMO therapies, down 3% year over year. The figure beat the Zacks Consensus Estimate of $227 million.
Sarepta generated $102 million from Elevidys sales, down 73% year over year, primarily due to its decision to suspend shipments to non-ambulatory patients in June 2025 amid safety concerns. The therapy’s sales also beat the Zacks Consensus Estimate of $97 million.
SRPT recorded $400.3 million in collaboration and other revenues, compared to $133.3 million in the year-ago period. This increase was primarily driven by higher collaboration revenues related to Roche’s (RHHBY - Free Report) declined option for certain program rights, milestone payments tied to the first commercial dosing of Elevidys in Japan and higher Elevidys supply shipments to Roche.
Sarepta and Roche entered into a licensing agreement in 2019 to develop Elevidys. Per the agreement, RHHBY has exclusive rights to launch and market Elevidys in ex-U.S. markets.
Discussion on SRPT’s Operating CostsAdjusted research and development (R&D) expenses totaled $137.5 million, down 82% year over year. This decline was primarily due to the recognition of $583.6 million in upfront and collaboration license fees paid to Arrowhead in the year-ago period.
Adjusted selling, general & administrative (SG&A) expenses declined 20% to $86.1 million, primarily due to the company’s restructuring plan launched last year in July.
SRPT Reiterates 2026 GuidanceSarepta expects net product guidance to be between $1.2 billion and $1.4 billion.
The company forecasts combined adjusted R&D and SG&A expenses in the $800-$900 million range.
Updates on SRPT’s Pipeline & Other NewsLast month, the company submitted regulatory filings to the FDA seeking to convert the accelerated approvals granted for Vyondys 53 and Amondys 45 into full/traditional approvals. These filings are supported by data from a late-stage confirmatory study and substantial real-world evidence.
In March, SRPT announced that screening and enrollment are underway in cohort 8 of the phase Ib ENDEAVOR study. This cohort is designed to improve the safety profile of Elevidys in non-ambulatory patients by combining it with an enhanced sirolimus-based immunosuppressive regimen. Data from this cohort will be used to determine whether administering sirolimus before or after Elevidys infusion can help reduce the risk of acute liver complications.
In March, Sarepta also reported promising early results from two ongoing phase I/II studies — one for SRP-1001 for facioscapulohumeral muscular dystrophy type I (FSHD1) and another for SRP-1003 for myotonic dystrophy type I (DM1). The data showed that both drugs, which were acquired from Arrowhead last year, achieved high muscle concentrations without dose-limiting toxicity in patients.
SRPT’s Zacks RankSarepta currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference at the InterContinental New York Barclay on Wednesday, May 20, at 8:30 a.m. ET.
The presentations will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large pharmaceutical companies are sitting on billions in cash while staring down looming patent cliffs.
That combination is creating a fertile backdrop for smaller biotech companies with strong pipelines, differentiated technology, and upcoming catalysts. Here are my top three biotech stocks for May.
Image source: Getty Images.
Schrödinger Schrödinger (SDGR 1.03%) develops physics-based software and artificial intelligence (AI) tools that pharmaceutical companies use to simulate how drug molecules behave before moving into expensive laboratory and human testing.
Major drugmakers use its platform to accelerate drug discovery in areas such as cancer, autoimmune diseases, and precision medicine. At the same time, the company also advances its own pipeline of internally developed drug candidates.
Worth noting: Schrödinger is one of the few AI-driven biotech companies that actually generates revenue, too. The company reported $256 million in total revenue for 2025, including $200 million in software revenue and annual contract value (ACV) of $198 million. Management is guiding for 10% to 15% ACV growth in 2026, with an expected range of $218 million to $228 million.
Today's Change
(
-1.03
%) $
-0.15
Current Price
$
14.45
The company's balance sheet also remains solid. Management has repeatedly emphasized that existing cash reserves support operations well into the company's path toward positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by the end of 2028.
What investors are really betting on, however, is the platform's ability to generate successful internal drug candidates. Schrödinger continues advancing oncology and precision medicine programs while maintaining partnerships with major pharmaceutical companies.
This is still a development-stage biotech story in many respects, but the software business gives the company a revenue foundation that most early stage biotech companies simply do not have. And that's not trivial.
Sarepta Therapeutics Sarepta Therapeutics (SRPT +0.93%) remains one of the most controversial stocks in biotech, but it also remains one of the few gene therapy companies generating substantial commercial revenue.
The company reported full-year 2025 net product revenue of $1.86 billion. Of that total, approximately $899 million came from Elevidys, Sarepta's one-time gene therapy designed to deliver a functional version of the dystrophin gene (a protein that helps keep muscle cells strong and stable during movement) to patients with Duchenne Muscular Dystrophy.
Another $966 million came from the company's PMO franchise, which includes a variety of drugs that help certain Duchenne patients produce shortened forms of the dystrophin protein.
Today's Change
(
0.93
%) $
0.14
Current Price
$
15.14
The problem is that safety concerns surrounding Elevidys continue to weigh heavily on investor sentiment. Multiple patient deaths tied to acute liver failure forced the company into shipment pauses, FDA scrutiny, and labeling changes over the past year.
Despite the controversy, Elevidys continues to generate significant commercial revenue. Sarepta treated more than 1,300 patients with Elevidys and maintained its 2026 revenue guidance of $1.2 billion to $1.4 billion.
The market is now trying to determine whether Sarepta can stabilize the safety narrative while continuing to expand its Duchenne Muscular Dystrophy franchise. This stock still carries significant risk. Ongoing regulatory scrutiny has weakened investor confidence, but unlike many biotech companies trading on future possibilities, Sarepta already has a large commercial business generating real cash flow. And a lot of it.
NRX Pharmaceuticals NRX Pharmaceuticals (NRXP 0.77%) remains highly speculative, but the company has begun to generate the kind of regulatory momentum that makes it attractive.
If you're unfamiliar, NRX is a small biotech company developing treatments for severe depression, suicidal bipolar disorder, and other serious central nervous system conditions. The company's lead drug candidate, NRX-101, is designed to help stabilize patients following ketamine treatment while potentially reducing relapse and suicidal risk.
Ketamine is a dissociative anesthetic used to rapidly treat severe depression and suicidal thoughts, particularly in patients who have not responded to traditional antidepressants.
The biggest recent development came in March, when the FDA informed the company it had not identified any major problems with how NRX's preservative-free ketamine performed compared to an already approved version of ketamine. The company now expects a potential FDA decision this summer.
More recently, NRX announced FDA clearance to proceed with a clinical trial combining NRX-101 with robotic-enabled transcranial magnetic stimulation for patients suffering from depression and suicidality.
Unlike larger biotech companies, NRX still carries substantial financing and execution risk. This remains a small-cap biotech company operating in a difficult capital environment.
Today's Change
(
-0.77
%) $
-0.03
Current Price
$
3.89
But mental health and neuropsychiatric treatment remain major unmet medical needs, and investors are paying increasing attention to companies targeting severe depression, PTSD, and suicidality. If NRX secures regulatory approval or delivers positive clinical data over the next 12 months, the stock could attract significantly more institutional attention.
Biotech investing is never about certainty. Clinical failures happen. Regulatory setbacks happen. Capital raises happen. But Schrödinger has a real software business supporting its AI platform, Sarepta has nearly $2 billion in annual product revenue despite ongoing controversy, and NRX has multiple regulatory catalysts approaching within the next several quarters.
That's why these are my top three biotech stocks for May 2026.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Fireside chat: Monday, June 8, at 10:40 a.m. ET at the Loews Miami Beach Hotel in Miami Beach, Fla. Oppenheimer CNS and Neuro-Muscular Summit Investor meetings: Wednesday, June 10, 2026 at The Bath Club i.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Sarepta Therapeutics (SRPT) or argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
